scholarly journals Eosinophilia in Patients with End Stage Renal Disease Undergoing Hemodialysis

2021 ◽  
Vol 27 (2) ◽  
pp. 67-70
Author(s):  
Kyoung Ha Kim ◽  
Tae Ik Chang ◽  
Seug Yun Yoon ◽  
Min-Young Lee ◽  
Namsu Lee ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Medical Records ◽  
Medical Center ◽  
Parasite Infection ◽  
University Hospital ◽  
History Of ◽  
Stage Renal Disease ◽  
End Stage ◽  
Specific Symptoms

Objective: Eosinophilia in patients on hemodialysis has already been reported. It has been associated with allergy to dialyzers and exaggerated activation of complement during hemodialysis. Its etiology, however, remains unknown. In addition, there are not enough studies on eosinophilia in patients on hemodialysis in Korea. Therefore, we performed this retrospective study to find out the prevalence and possible etiologic factors of blood eosinophilia in patients undergoing hemodialysis.Methods: Between January 2013 to December 2015, the patients hospitalized for hemodialysis at Soonchunhyang University Hospital and National Health Insurance Service Medical Center (Ilsan Hospital) were included in this study. Eosinophilia was defined when absolute eosinophil count was greater than 500/μL, respectively. We retrospectively reviewed the medical records of patients about parasite infection, other malignancies, and history of kidney transplantation.Results: Of the 2,155 patients hospitalized for hemodialysis at two centers, 1,057 patients (49%) were found to have eosinophilia. We investigated 1,199 patients’ information (Soonchunhyang University Hospital) by the medical records. Two hundred two patients (16.8%) had no identifiable and/or possible causes. Only two patients complained of symptoms such as itching. Steroids were administered to control symptoms, and both patients had normal eosinophil levels, and steroids were discontinued. Other patients did not complain of specific symptoms associated with eosinophilia and did not take medication such as steroids. Eosinophilia was improved in 49% of patients without special treatments.Conclusion: We found that the eosinophil counts in patients with end stage renal disease on hemodialysis were frequently elevated. However, in most cases, eosinophilia was not clinically relevant.

scholarly journals Analysis of Endocan Levels in Hypertensive Patients as Risk Factors of Chronic Kidney Disease

2020 ◽  
Vol 27 (1) ◽  
Author(s):  
Suryani Jamal ◽  
Uleng Bahrun ◽  
Ibrahim Abdul Samad ◽  
Fitriani Mangarengi ◽  
Hasyim Kasim ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Stage Ii ◽  
University Hospital ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Elisa Method ◽  
Cross Sectional ◽  
Stage Renal Disease ◽  
End Stage

This study aimed to analyze endocan levels as a marker of endothelial dysfunction in the control group, patients withstage I hypertension, stage II hypertension, and patients with end-stage renal disease. Endocan levels were measured withESM-1 (endocan) kit by Enzyme-Linked Immunosorbent Assay (ELISA) method. This study used a cross-sectional methodand was conducted in Dr. Wahidin Sudirohusodo Hospital, Makassar and Hasanuddin University Hospital from Septemberto October 2017. There were 83 samples in this study, consisting of 12 samples in the control group, 22 samples of stage Ihypertension, 28 samples of stage II hypertension, and 21 samples of end-stage renal disease aged 20-90 years old. Thisstudy showed significantly higher endocan levels in patients with stage II hypertension and end-stage renal disease(p< 0.05). Endocan levels were significantly higher (p<0.05) in patients with end-stage renal disease compared with thecontrol group and patients with stage I hypertension; but not significantly higher (p > 0.05) compared to patients with stageII hypertension. Also, the median of endocan levels in patients with the end-stage renal disease was higher (309,850 ng/L)compared to patients with stage II hypertension (273,050 ng/L).

History of hypertension in patients treated for end-stage renal disease

1997 ◽  
Vol 15 (4) ◽  
pp. 451-456 ◽  
Author(s):  
Thomas V. Perneger ◽  
Paul K. Whelton ◽  
Michael J. Klag
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
History Of ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals A Case of Psoriasis Vulgaris Treated with Brodalumab in a Hemodialysis Patient with End-Stage Renal Disease due to Diabetic Nephropathy

2020 ◽  
Vol 2020 ◽  
pp. 1-4
Author(s):  
Masafumi Ishibashi ◽  
Rie Shiiyama
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Psoriasis Vulgaris ◽  
Lavage Fluid ◽  
Skin Lesions ◽  
Dietary Control ◽  
Serious Adverse Events ◽  
History Of ◽  
Stage Renal Disease ◽  
End Stage

Psoriasis vulgaris is not frequently seen in patients on hemodialysis. However, these patients have limited treatment for psoriasis due to concerns about complications. We report the case of a psoriatic patient with end-stage renal disease on hemodialysis, safely treated with brodalumab. A 60-year-old man who presented with a 20-year history of recalcitrant severe psoriasis. He had diabetes from 40 years ago, and hemodialysis was initiated due to the progression of renal dysfunction two months ago. He was treated with brodalumab, and skin lesions improved markedly. He began to have a chronic cough four months after starting brodalumab. CT showed diffuse ground-glass shadow and pleural effusion in both lungs. Transbronchial lung biopsy showed no findings suggestive of interstitial pneumonia. In bronchoalveolar lavage fluid, mycobacteria and fungi were not identified. The T-SPOT.TB test was negative. It was considered to be a symptom of overflow due to excessive fluid volume based on insufficient dietary management. Brodalumab was continued, and respiratory symptoms improved with proper weight setting and adequate dietary control. No recurrence of rash has been seen 12 months after the initiation of brodalumab. There were no serious adverse events.

scholarly journals Electroconvulsive Therapy in a Renal Transplantation Patient: A Rare Combination of Disease and Treatment

2020 ◽  
Vol 2020 ◽  
pp. 1-4
Author(s):  
Giovanni Malaty ◽  
Kerilyn Godbe ◽  
Mehdi Elmouchtari ◽  
Gurjot Malhi ◽  
Justin White ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Renal Transplant ◽  
Renal Disease ◽  
Electroconvulsive Therapy ◽  
End Stage Renal Disease ◽  
Psychotic Symptoms ◽  
Safety And Efficacy ◽  
History Of ◽  
Stage Renal Disease ◽  
End Stage

The safety and efficacy of electroconvulsive therapy (ECT) for the treatment of psychiatric disorders have been demonstrated in a wide variety of patients, including postoperative patients and those who are pregnant. While several reports highlight the safety of this treatment in heart and liver transplantation patients, there is a relative lack of literature detailing the safety profile of ECT in an individual with recent kidney transplantation. Here, we explore the case of a patient with a recent renal transplant secondary to diabetes-related end-stage renal disease (ESRD) who underwent a successful course of ECT treatment. A 57-year-old Caucasian male with a past psychiatric history of schizoaffective disorder, bipolar type, and a past medical history of end-stage renal disease with recent right renal transplantation was admitted to the inpatient psychiatry unit. The admission was via a temporary detention order (TDO) for suicidality and auditory hallucinations promoting self-harm. The patient’s depressive and delusional history was well-documented and had been refractory to several courses of psychotherapeutic and pharmacologic management. Electroconvulsive therapy was subsequently initiated and was well-tolerated. Treatments progressively alleviated his depressive and psychotic symptoms and did not adversely affect the function of his transplanted kidney, which was closely monitored throughout the treatment process. This case demonstrated the safety and efficacy of ECT treatment in an individual with recent renal transplant and may prompt further trials into establishing safety and efficacy in larger study populations.

scholarly journals Risk of End-Stage Renal Disease in Psoriatic Patients: Real-World Data from a Nationwide Population-Based Cohort Study

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Eun Lee ◽  
Ju Hee Han ◽  
Chul Hwan Bang ◽  
Seung Ah Yoo ◽  
Kyung Do Han ◽  
...  
Keyword(s):  
Cohort Study ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Treated Group ◽  
Population Based ◽  
Control Group ◽  
Real World Data ◽  
History Of ◽  
Stage Renal Disease ◽  
End Stage

Abstract Psoriasis is a chronic inflammatory skin disorder mediated by the T-cell–related immune response. Psoriatic patients may have a variety of comorbidities, but their risk of end-stage renal disease (ESRD), particularly according to the subtype of psoriasis, is unclear. We investigated the risk of ESRD in patients with psoriasis according to the subtype of psoriasis and history of systemic therapy for psoriasis. A total of 2,121,228 adults (1,590,921 in the control group and 530,307 in the psoriasis group) were enrolled in this nationwide population-based cohort study until 2015. During follow-up, 1,434 of the subjects in the psoriasis group developed ESRD. After adjusting for confounding factors, psoriasis was associated with the risk of ESRD (hazard ratio (HR) 1.58, 95% confidence interval [95% CI] 1.47–1.68). The psoriatic arthritis group (HR 7.60, 95% CI 1.90–30.41) had a higher risk of ESRD than the control group. Interestingly, no such association was detected in the systemically treated group (HR 1.07, 95% CI 0.80–1.41). Moreover, the acitretin-treated group had a lower risk of ESRD (HR 0.658, 95% CI, 0.494–0.875) than the non-systemically treated group. In conclusion, the risk of developing ESRD in patients with psoriasis differed according to the type of treatment and the presence of arthritis.

Mortality of Chronic Hemodialysis and Renal Transplantation in Pediatric End-Stage Renal Disease

PEDIATRICS ◽  
1981 ◽  
Vol 67 (3) ◽  
pp. 412-416 ◽  
Author(s):  
Ellis D. Avner ◽  
William E. Harmon ◽  
Warren E. Grupe ◽  
Julie R. Ingelfinger ◽  
Angelo J. Eraklis ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Medical Center ◽  
Current Treatment ◽  
Chronic Hemodialysis ◽  
Actuarial Survival ◽  
Endstage Renal Disease ◽  
Stage Renal Disease ◽  
End Stage

The long-term mortality of chronic hemodialysis and renal transplantation was analyzed in all children treated for end-stage renal disease at Children's Hospital Medical Center over the past 8½ years. A total of 216 transplantation or dialysis courses in 120 patients were studied. No patients were excluded from treatment or analysis. Overall actuarial survival was 92% at six months, 90% at 12 months, and 89% at five years. When actuarial survival for each form of treatment was examined, patient survival was 100% at six months and 95% at five years for chronic hemodialysis; 92% at six months and five years for living related transplantation; and 88% at six months and 85% at five years for cadaveric transplantation. We conclude that most children with endstage renal disease can be kept alive with current treatment programs, and that the mortality of chronic hemodialysis in children is comparable to that of renal transplantation.

Family history of end-stage renal disease does not predict dialytic survival

2001 ◽  
Vol 38 (3) ◽  
pp. 547-552 ◽  
Author(s):  
Barry I. Freedman ◽  
J.Michael Soucie ◽  
Barbara Kenderes ◽  
Jenna Krisher ◽  
Leland E. Garrett ◽  
...  
Keyword(s):  
Family History ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
History Of ◽  
Stage Renal Disease ◽  
End Stage
Sign in / Sign up

Export Citation Format

Share Document